KR20150081255A - Ｈｉｖ 중성화 항체 식별 방법 - Google Patents

Ｈｉｖ 중성화 항체 식별 방법 Download PDF

Info

Publication number
KR20150081255A
KR20150081255A KR1020157008791A KR20157008791A KR20150081255A KR 20150081255 A KR20150081255 A KR 20150081255A KR 1020157008791 A KR1020157008791 A KR 1020157008791A KR 20157008791 A KR20157008791 A KR 20157008791A KR 20150081255 A KR20150081255 A KR 20150081255A
Authority
KR
South Korea
Prior art keywords
antibody
binding
fusion protein
hiv
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157008791A
Other languages
English (en)
Korean (ko)
Inventor
줄리안 미구엘 블란코 아버스
조지 칼리로 몰리나
Original Assignee
라보라토리오스 델 드라. 에스테브.에스.에이.
푼다시오 프리바다 인스티튜트 데 레세르사 데 라 시다 - 카이사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라보라토리오스 델 드라. 에스테브.에스.에이., 푼다시오 프리바다 인스티튜트 데 레세르사 데 라 시다 - 카이사 filed Critical 라보라토리오스 델 드라. 에스테브.에스.에이.
Publication of KR20150081255A publication Critical patent/KR20150081255A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K16/1045—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
KR1020157008791A 2012-09-06 2013-09-06 Ｈｉｖ 중성화 항체 식별 방법 Withdrawn KR20150081255A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382342.9 2012-09-06
EP12382342.9A EP2706356A1 (en) 2012-09-06 2012-09-06 Methods for identifying HIV neutralizing antibodies
PCT/EP2013/068446 WO2014037490A1 (en) 2012-09-06 2013-09-06 Methods for identifying hiv neutralizing antibodies

Publications (1)

Publication Number Publication Date
KR20150081255A true KR20150081255A (ko) 2015-07-13

Family

ID=46829683

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157008791A Withdrawn KR20150081255A (ko) 2012-09-06 2013-09-06 Ｈｉｖ 중성화 항체 식별 방법

Country Status (16)

Country Link
US (1) US9952218B2 (https=)
EP (2) EP2706356A1 (https=)
JP (1) JP6282655B2 (https=)
KR (1) KR20150081255A (https=)
CN (1) CN104755933B (https=)
AU (1) AU2013311626A1 (https=)
BR (1) BR112015004970A2 (https=)
CA (1) CA2884165A1 (https=)
ES (1) ES2643268T3 (https=)
IL (1) IL237613A0 (https=)
IN (1) IN2015DN02730A (https=)
MX (1) MX2015003047A (https=)
PT (1) PT2893349T (https=)
RU (1) RU2015112297A (https=)
WO (1) WO2014037490A1 (https=)
ZA (1) ZA201502210B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106166313B (zh) * 2016-07-01 2018-09-07 浙江大学 一种艾滋病孕妇血液净化器
CN106075626B (zh) * 2016-07-01 2018-06-26 浙江大学 一种艾滋病血液净化治疗仪

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US7115262B1 (en) * 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
WO2003040311A2 (en) * 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
EP1523492A4 (en) * 2002-07-23 2006-05-10 Univ Duke IGG FC / HIV GP120 / C3D FUSION PROTEIN
US8197819B2 (en) * 2004-06-08 2012-06-12 Novartis Vaccines And Diagnostics, Inc. Env polypeptide complexes and methods of use
ATE471947T1 (de) * 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
CN101551392A (zh) * 2008-01-22 2009-10-07 厦门大学 一种检测人乳头瘤病毒中和抗体的方法
CN101846679A (zh) * 2009-03-25 2010-09-29 邢安辉 筛选含有外源融合基因HIV/env/IFNα-2b的重组痘苗病毒的方法
EP3957651A1 (en) * 2010-05-21 2022-02-23 The United States of America, as Represented By the Secretary, Department of Health and Human Services High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins

Also Published As

Publication number Publication date
PT2893349T (pt) 2018-04-12
WO2014037490A1 (en) 2014-03-13
IN2015DN02730A (https=) 2015-09-04
MX2015003047A (es) 2015-07-14
AU2013311626A1 (en) 2015-04-30
CN104755933B (zh) 2017-06-09
CA2884165A1 (en) 2014-03-13
EP2706356A1 (en) 2014-03-12
EP2893349B1 (en) 2017-08-16
CN104755933A (zh) 2015-07-01
EP2893349A1 (en) 2015-07-15
JP6282655B2 (ja) 2018-02-21
ZA201502210B (en) 2016-11-30
JP2015530575A (ja) 2015-10-15
US9952218B2 (en) 2018-04-24
RU2015112297A (ru) 2016-10-27
ES2643268T3 (es) 2017-11-21
US20150233924A1 (en) 2015-08-20
IL237613A0 (en) 2015-04-30
HK1211694A1 (en) 2016-05-27
BR112015004970A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
US20250129171A1 (en) Car t-cell therapy directed to lhr for the treatment of solid tumors
US11214616B2 (en) Anti-TIGIT antibodies and their use as therapeutics and diagnostics
US10711064B2 (en) Lym-1 and Lym-2 targeted CAR cell immunotherapy
Ou et al. Role of protein disulfide isomerase and other thiol-reactive proteins in HIV-1 envelope protein-mediated fusion
JP2025013911A (ja) 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用
Stefanova et al. HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression.
Bego et al. Vpu exploits the cross-talk between BST2 and the ILT7 receptor to suppress anti-HIV-1 responses by plasmacytoid dendritic cells
JP2013538555A (ja) Ｍｈｃクラスｉｉとグルタミン酸デカルボキシラーゼ（ｇａｄ）自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
US20230235050A1 (en) Single-domain antibodies directed against lilrb2
US20200016201A1 (en) Chimeric antigen receptors and compositions and methods of use thereof
JP2013535963A (ja) Ｍｈｃクラスｉｉと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
Moody et al. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines
CN117487012A (zh) 用于抑制纤维粘连蛋白与lilrb4的结合的抗lilrb4抗体或其衍生物
KR20200003915A (ko) 높은 이중 ＨＩＶ 항바이러스 활성과 면역조절 활성을 갖는 Ｆｃ-융합 단백질 유도체
Ringe et al. Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity
EP2893349B1 (en) Methods for identifying hiv neutralizing antibodies
US8637234B2 (en) Molecular scaffolds for HIV-1 epitopes
CN114316062B (zh) 靶向HIV gp120蛋白和人CD3分子的多特异性抗体及其应用
Hwang et al. A high affinity monoclonal antibody against HLA-E-VL9 enhances natural killer cell anti-tumor killing
HK1211694B (en) Methods for identifying hiv neutralizing antibodies
RU2774782C2 (ru) Производные слитого с Fc белка с высокой двойной активностью: противовирусной активностью в отношении ВИЧ и иммуномодулирующей активностью
Gapp Mechanistic insight into the CD32-driven enhancement of HIV-1 susceptibility of resting CD4 T cells
TW202317619A (zh) 針對抗cd79b抗體的抗獨特型抗體
WO2024019110A1 (ja) ＳＡＲＳ－ＣｏＶ－２に対する抗体
畑山靖佳 et al. Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000